Belgium Allows Fully Autonomous Vehicles To Be Tested on the Public Highway
Client Alert | 1 min read | 05.03.18
On May 1, 2018, Belgium became one of the first European countries to allow fully autonomous vehicles to be tested on the public highway without a driver.
Back in September 2016, the Belgian federal government issued a set of guidelines for organizations wishing to test driver assistance and partially or fully automated vehicle technologies on public roads or in other public places within Belgium. These guidelines list the minimum conditions and safety requirements which the organization responsible for the testing must comply with in order to guarantee road safety and minimize potential risks.
However, implementation of these guidelines required adaptation of the Belgian traffic code to allow for their unambiguous application. Therefore, on March 18, 2018, the Belgian federal government passed a royal decree introducing a new provision (article 59/1) which allows the federal Minister of Mobility to deviate from all provisions of the Belgian traffic code in the framework of experiments with automated vehicles. Such deviation is subject to conditions and must be for a limited time.
As a result of the adoption of this new provision, the federal Minister of Mobility can now allow the testing of fully autonomous vehicles on public roads without a driver, but the test must be supervised by an operator acting from a control room outside the car.
Any organization interested in carrying out such tests can file an application at the Ministry of Mobility.
Contacts
Insights
Client Alert | 9 min read | 10.21.26
The life sciences sector is uniquely vulnerable to the inherent risks of AI-generated evidence in drug development and discovery. This client alert focuses on five core challenges: hallucinations, skewed predictions from unrepresentative training data, the opacity of AI reasoning, input sensitivity that undermines reproducibility, and adversarial manipulation of training data. To address these risks, companies should use experimental validation and human oversight as the common legal and regulatory safety net. This entails among other measures auditing AI outputs, characterizing training data, and structural oversight. Companies also should prepare for evolving frameworks and guidance from the U.S. Food and Drug Administration (FDA) and the European Union (EU) that address use of AI in drug discovery and development .
Client Alert | 2 min read | 10.21.26
Client Alert | 3 min read | 10.21.26
Private Investigations Act Series: Temporal, material and territorial scope
Client Alert | 7 min read | 10.21.26
